Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

101.17 -0.83 (-0.82%)
Streaming Delayed Price Updated: 1:13 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 21, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 16, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant... 
From Moderna, Inc.
Via AccessWire
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273) Moderna expects... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its... 
From Moderna, Inc.
Via AccessWire
Moderna Announces Its Global Public Health Strategy
Moderna announces commitment to advance vaccines targeting 15 pathogens identified as biggest public health risk by WHO and CEPI into clinical studies by 2025 Moderna launches mRNA Access, a new... 
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities Moderna investing up to $500 million to produce up to 500 million doses each year for the African... 
From Moderna, Inc.
Via AccessWire
Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia
The Americas Enterprise Solutions Hub will support the U.S., Canada and Latin America and is in addition to Moderna's International Enterprise Solutions Hub in Warsaw, Poland Atlanta selected due to... 
From Moderna, Inc.
Via AccessWire
Moderna to Present at Upcoming Conferences in March 2022
CAMBRIDGE, MA / ACCESSWIRE / March 2, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the... 
From Moderna, Inc.
Via AccessWire
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
Announcement follows CHMP's previous decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include adolescents 12 years of age and older.... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of... 
From Moderna, Inc.
Via AccessWire
Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration
From Thermo Fisher Scientific Inc. and Moderna, Inc.
Via Business Wire
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022 Moderna also supplies the Company's... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in... 
From Moderna, Inc.
Via AccessWire
Moderna Expands Its mRNA Pipeline with Three New Development Programs
mRNA-1608 is a vaccine candidate against Herpes simplex virus (HSV) mRNA-1468 is a vaccine candidate against varicella-zoster virus (VZV) to reduce the rate of herpes zoster (shingles) mRNA-4359 is a... 
From Moderna, Inc.
Via AccessWire
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)
CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries
Announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region Local commercial... 
From Moderna, Inc.
Via AccessWire
Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market
Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years.... 
Via FinancialNewsMedia
Exposures COVID-19
Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years
Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain CAMBRIDGE, MA and MADRID,... 
From Moderna, Inc.
Via AccessWire
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries
Announcement reinforces Moderna's commitment to Asia and vision as a global commercial enterprise New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong; providing local... 
From Moderna, Inc.
Via AccessWire
Moderna Chief Technical Operations and Quality Officer Juan Andres Elected to National Academy of Engineering
CAMBRIDGE, MA / ACCESSWIRE / February 9, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Juan Andres, Chief... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine
CAMBRIDGE, MA / ACCESSWIRE / February 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
CAMBRIDGE, MA / ACCESSWIRE / February 3, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live... 
From Moderna, Inc.
Via AccessWire
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose SPIKEVAX has received approval by regulators in more than 70... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
Phase 1 trial aims to build on response seen in proof-of-concept trial CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and... 
From Moderna, Inc.
Via AccessWire
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
Phase 2 study of Omicron-specific booster candidate (mRNA-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mRNA-1273 and another including... 
From Moderna, Inc.
Via AccessWire
Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries Product sales for 2021 approximately $17.5 billion... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
Collaboration will combine Carisma's engineered macrophage technology with Moderna's mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration... 
From Moderna, Inc.
Via AccessWire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.